Herlander Marques

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5198025/publications.pdf

Version: 2024-02-01

33 papers	469 citations	758635 12 h-index	713013 21 g-index
35 all docs	35 docs citations	35 times ranked	1065 citing authors

#	Article	IF	Citations
1	A polygenic risk score for multiple myeloma risk prediction. European Journal of Human Genetics, 2022, 30, 474-479.	1.4	5
2	ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort. International Journal of Molecular Sciences, 2022, 23, 201.	1.8	7
3	Circulating lncRNA- and miRNA-Associated ceRNA Network as a Potential Prognostic Biomarker for Non-Hodgkin Lymphoma: A Bioinformatics Analysis and a Pilot Study. Biomedicines, 2022, 10, 1322.	1.4	2
4	Common gene variants within 3â€²â€untranslated regions as modulators of multiple myeloma risk and survival. International Journal of Cancer, 2021, 148, 1887-1894.	2.3	3
5	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	2.3	3
6	Genetically determined telomere length and multiple myeloma risk and outcome. Blood Cancer Journal, 2021, 11, 74.	2.8	10
7	Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives. Biomedicines, 2021, 9, 1934.	1.4	1
8	miRNA- and lncRNA-Based Therapeutics for Non-Hodgkinâ€™s Lymphoma: Moving towards an RNA-Guided Precision Medicine. Cancers, 2021, 13, 6324.	1.7	3
9	The mediator role of unmet needs on quality of life in myeloma patients. Quality of Life Research, 2020, 29, 2641-2650.	1.5	10
10	Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma â€“ MCT1 as potential target in diffuse large B cell lymphoma. Cellular Oncology (Dordrecht), 2019, 42, 303-318.	2.1	34
11	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leukemia and Lymphoma, 2019, 60, 1803-1811.	0.6	11
12	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. British Journal of Haematology, 2018, 183, 375-384.	1.2	11
13	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	2.3	8
14	Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis. BMC Cancer, 2016, 16, 535.	1.1	47
15	Absence of microsatellite instability andBRAF(V600E) mutation in testicular germ cell tumors. Andrology, 2016, 4, 866-872.	1.9	18
16	Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. Tumor Biology, 2016, 37, 4901-4907.	0.8	13
17	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	0.8	16
18	Methodology for single nucleotide polymorphism selection in promoter regions for clinical use. An example of its applicability. International Journal of Molecular Epidemiology and Genetics, 2016, 7, 126-136.	0.4	1

#	Article	IF	Citations
19	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	5.8	38
20	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer, 2015, 22, 545-559.	1.6	11
21	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. International Journal of Cancer, 2015, 136, E351-8.	2.3	30
22	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associationsâ€"An Extensive Replication of the Associations from the Candidate Gene Era. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 670-674.	1.1	13
23	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a caseâ€"control study in the context of the IMMEnSE consortium. Journal of Human Genetics, 2013, 58, 155-159.	1.1	5
24	Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a caseâ€"control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Leukemia, 2012, 26, 1419-1422.	3.3	14
25	Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkinâ€™s lymphoma is not associated with prognosis. Oncology Letters, 2012, 4, 1285-1289.	0.8	5
26	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. British Journal of Haematology, 2012, 158, 805-809.	1.2	19
27	The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes and Immunity, 2012, 13, 197-201.	2.2	35
28	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the <scp>IMME</scp>n<scp>SE</scp> consortium. British Journal of Haematology, 2012, 157, 331-338.	1.2	13
29	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). International Journal of Oncology, 2011, 40, 625-38.	1.4	14
30	Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium. Blood, 2011, 118, 5014-5014.	0.6	0
31	Association of adult mastocytosis with M541L in the transmembrane domain of KIT. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1118-1119.	1.3	4
32	Indeterminate Cell Histiocytosis in Association with Acute Myeloid Leukemia. Dermatology Research and Practice, 2010, 2010, 1-4.	0.3	22
33	FcÎ³RIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genetics and Cytogenetics, 2008, 183, 35-40.	1.0	40